Antiendotoxin strategies for the prevention and treatment of septic shock

Drugs

Volumn 55, Issue 4, 1998, Pages 497-508

  Opal, Steven M ^a,b   Yu Jr , Richard L ^a  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE; CD14 ANTIGEN; E 5531; ENDOTOXIN; ENDOTOXIN ANTIBODY; HIGH DENSITY LIPOPROTEIN; L 161240; L 573655; POLYMYXIN B; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CRITICAL ILLNESS; DRUG BINDING; DRUG EFFICACY; EFFECTOR CELL; GRAM NEGATIVE INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TOXIN SYNTHESIS; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD14; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL VACCINES; BLOOD PROTEINS; ENDOTOXEMIA; ENDOTOXINS; GRAM-NEGATIVE BACTERIA; HUMANS; LIPID A; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; RECOMBINANT PROTEINS; SHOCK, SEPTIC;

EID: 0031955291     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855040-00002     Document Type: Review

References (81)

1. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical trial of E5, a monoclonal antibody to endotoxins: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994-1006
2. Baumgarlner J-D, Glauser M-P, et al. Immunotherapy of endotoxemia and septicemia. Immunobiology 1993; 187: 464-77
3. Cross AS, Opal SM. Therapeutic intervention in sepsis with antibody in endotoxin: is there a future? J Endotoxin Res 1994; 1: 57-69
4. Rietsehel ET, Kirikae T, Schade FU, et al. Bacterial endotoxin: molecular mechanisms of structure to activity and function. FASEB J 1994; 218: 217-25
5. Horn DL, Opal SM, Lomastro E. Antibiotics, cytokines, and ecndotoxin: a complex and evolving relationship in Gram-negative sepsis. Scand J Infect Dis 1996; 101: 9-13
6. Opal SM. Lessons learned from clinical trials of sepsis. J Endotoxin Res 1995; 2: 1-6
7. Zeigler EJ, Fisher Jr CJ, Sprung CL, et al. Treatment of gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-18
8. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of F5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266: 1097-102
9. Ulevitch RJ, Dunn DL, Fink MP, et al. Endotoxin-related intra-cellular pathways: implications for therapeutic intervention. Shock 1996; 6: 1-2
10. Rietschel ET, Brade H, Holst O, et al. Bacterial endotoxin: chemical composition, biological recognition, host response, and immunological detoxification. Curr Topics Microbiol Immunol 1996; 216: 39-81
11. Mamat U, Rietschel ET, Schmidt G. Repression of lipopolysaccharide biosynthesis in Escherichia coli by an antisense RNA of Acetobacter methanolicus phage Acml. Mol Microbiol 1995; 15: 1115-25
12. Galloway SM, Raetz CR. J Bi A mutant of Escherichia coli defective in the first step of endotoxin biosynthesis. Chem 1990; 265 (11): 6394-402
13. Vuorio R, Vaara M. The lipid A biosynthesis mutation of lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility. Antimicrob Agents Chemother 1992 Apr; 36 (4): 826-9
14. Raetz CR. Bacterial endotoxins: extraordinary lipids that activate eukaryotic signal transduction. J Bacteriol 1993; 175 (18): 5745-53
15. Young K, Silver LL, Bramhill D, et al. The envA permeability/cell division gene of Escherichia coli encodes the second enzyme of lipid A biosynthesis. J Biol Chem 1995 Dec 22; 270 (51): 30384-91
16. Onishi HR, Pelak BA, Gerckens LS, et al. Antibacterial agents that inhibit lipid A biosynthesis. Science 1996; 274: 980-2
17. Kelly TM, Stachula SA, Raetz CRH, Anderson MS. The firA gene of Escherichia coli encodes UDP-3-O-(R-3-hydroxymyristoyl)-glucosamine-N-acyltransferase. J Biol Chem 1993; 268 (26): 19866-74
18. Goldman R. Kohlbrenner W, Laney P, et al. Antibacterial agents specifically inhibiting lipopolysaccharide synthesis. Nature 1987; 329: 162-4
19. Hammond SM, Claesson A, Jansson AM, et al. A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis. Nature 1987; 327: 730-2
20. Brande AI, Ziegler EJ, Douglas H, et al. Antibody to cell wall glycolipid of gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J Infect Dis 1977; 136: S167-73
21. Warren HS, Amato SF, Fitting C, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993; 177: 89-97
22. Baumgartner J-D, Heumann D, Gerain J, et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin-6: comparison of O-side chain specific antibodies with core LPS antibodies. J Exp Med 1990; 171: 889-96
23. Bhart NM, Bieber MM, Chapman CJ, et al. Human anti-lipid A monoclonal antibodies hind to human B cells and i-antigen on core red blood cells. J Immunol 1993; 151: 5011-21
24. Quezado ZMM, Natanson C, Alling DW, et al. A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA 1993; 269: 2221-7
25. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 274: 172-7
26. Nys M, Damas P, Joassin L, et al. Sequential anti-core glycolipid immunoglobulin antibody activities with and without septic shock and their relation to outcome. Ann Surg 1993; 217: 300-6
27. DiPadova FE, Barclay R, Brade H, et al. SDZ219-800: a chimeric broadly cross-reactive and cross-neutralizing anticore LPS antibody [abstract no. 12.3]. Circ Shock 1993; 1 Suppl. 47
28. Bhattercharjee AK, Opal SM, Taylor R, et al. A non-covalent complex vaccine prepared with detoxified E. coli J5 LPS and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteria. J Infect Dis 1996; 173: 1157-62
29. Bhattercharjee AK, Opal SM, Palardy JE, et al. Affinity purified E. coli J5 LPS-specific IgG protects neutropenic rats against gram-negative sepsis J Infect Dis 1994; 170: 622-9
30. Donta ST, Peduzzi P, Cross AS, et al. Immunoprophylaxis against Klebsiellu and Pseudomonas aeruginosa infections. J Infect Dis 1996; 174: 537-43
31. Ooi CE, Weiss J, Elsbach P. Structural and functional organization of the human neutrophil 60kDa bactericidal/permeability-increasing protein. Agents and Actions 1991; 34: 274-7
32. Marra MN, Wilde CG, Griffith JE, et al. Bactericidal/permeability-increasing protein has endotoxin-neutralizing ability. J Immunol 1990; 144: 662-6
33. Elsbach P, Weiss J. Bactericidal/permeability-increasing protein and host defense against gram-negative bacteria in endotoxin. Curr Opin Immunol 1993; 5: 103-7
34. Marra MN, Wilde CG, Collins MS, et al. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148: 532-7
35. 23, a recombinant fragment of bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994; 62: 1185-91
36. Schumann RR, Leong SR, Flaggs GW. Structure and function of lipopolysaccharide-binding protein. Science 1992; 49: 1431-3
37. Opal SM, Palardy JE, Marra MN, et al. Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet 1994; 344: 429-31
38. Bermer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 4.5 angstrom resolution. Science 1997; 276: 1861-4
39. 23) J Infect Dis 1995; 172: 144-51
40. 21 in children with severe meningococcemia [abstract no. 414]. Infectious Disease Society of America Annual Meeting; Sept 15 1997: San Francisco (CA)
41. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181: 1743-54
42. Flegel WA, Wolpl A, Munnel DA, et al. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237-45
43. Levine DM, Parker TS, Donnelly TM, et al. In-vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-4
44. Pajkrt D, Doran JE, Coster F, et al. Anti-inflammatory affects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-8
45. Lerch PG, Fortsch V, Hodler G, et al. Production and characterization of a reconstituted high density lipoprotein (rHDL) for therapeutic application. Vox Sang 1996; 71: 155-64
46. Kodama M, Tani T, Hanasawa K. Extracorporeal removal of endotoxin in the septic patients by loraymyxin - clinical results in a phase II and III study in Japan [abstract]. Shock 1997; 7 Suppl.: 6
47. Hanasawa K, Tani T, Kodama M. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet 1989; 168: 323-31
48. Weber C, Rajnoch C, Schima H, et al. The microspheres based detoxification system (MDS). Int J Artil Organs 1994; 17 (11): 595-602
49. Lonergan JM, Orlowski JP, Sato T, et al. Extracorporeal endotoxin removal in a canine model of septic shock. ASAIO J 1994; 40: M654-7
50. Aoki H, Kodama M, Tani T, et al. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167: 412-7
51. Palmer JD, Rifkind D. Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Gynecol Obstet 1974; 138: 755-9
52. Cheadle WG, Hanasawa K, Gallinaro RN, et al. Endotoxin filtration and immune stimulation improve survival trom gram-negative sepsis. Surgery 1991; 110: 785-92
53. Sato T, Orlowski JP, Zhorowski M. Experimental study of extracorporeal perfusion for septic shock. ASAIO J 1993; 39: M790-3
54. Kodama M, Tani T, Maekawa K, et al. Endotoxin eliminating therapy in patients with severe sepsis-direct hemoperfusion using polymyxin B immobilized fiber column. J Endotoxin Res. In press
55. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Ann Rev Med 1987; 38: 417-32
56. Lynn WA, Golenbock DT. Lipopolysaccharide antagonists. Immunol Today 1992; 13: 271-6
57. Krauss JH, Seydel U, Weckesser J, et al. Structural analysis of the nontoxic lipid A of Rhodobacter capsulatus 37b4. Eur J Biochem 1989; 180: 519-6
58. Loppnow H, Libby P, Freudenberg MA, et al. Cytokine induction by LPS corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 1990; 558: 3743-50
59. Kawata T, Bristol J, Mcguigan L, et al. Anti-endotoxin activities of E5531, a novel synthetic derivative of lipid A [abstract no. 1360]. Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14 Oct 1992: 337
60. Christ WJ, Osama A, Robidoux ALC, et al. E5531 a pure endotoxin antagonist of high potency. Science 1995 268: 80-3
61. Kawata T, Bristol JR, Rose JR, et al. Anti-endotoxin activity of a novel synthetic lipid A analog. Prog Clin Biol Res 1995; 392: 499-509
62. Crosby HA, Bion JF, Penn CW, et al. Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol 1994; 40: 23-30
63. Kawata T, Bristol JR, Rose JR, et al. Specific lipid A analog which exhibits exclusive antagonism of endotoxin. In: Morrison D, Ryan J, editors. Novel therapeutic strategies in the treatment of sepsis. New York: Marcel Dekker, Inc., 1996; 171-86
64. Ferrero E, Jiao D, Tsuberi BZ, et al. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci USA 1993; 90: 2380-4
65. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Ann Rev Immunol 1995; 13: 437-57
66. Arditi M, Zhou J, Dorio R, et al. Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun 1993; 61: 3149-56
67. Delude RL, Savedra Jr R, Zhao HL. CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Proc Natl Acad Sci USA 92: 9288-92
68. Kusunoki T, Hailman E, Juan TS-C, et al. Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 1995; 182: 1673-82
69. Pugin J, Heumann D, Tomasz A, et al. CD14 as a pattern recognition receptor. Immunity 1994; 1: 509-16
70. Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4: 407-14
71. McGinley MD, Norhi LO, Kelley MJ, et al. CD14: physical properties and identification of an exposed site that is protected by a lipopolysaccharide. J Biol Chem 1995; 270: 5213-8
72. Juan TS-C, Hailman E, Kelley MJ, et al. Identification of lipopolysaccharide binding domain in CD14 between amino acids 57 and 64. J Biol Chem 1995; 270: 5219-24
73. Shapiro RA, Cunningham MD, Ratcliffe K, et al. Identification of CD14 residues involved in specific lipopolysaccharide recognition. Infect Immun 1997; 65: 293-7
74. Wright SD. CD14 and innate recognition of bacteria. J Immunol 1995; 155: 6-8
75. Leturcq DG, Moriarty AM, Talbott G, et al. Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 1946; 98: 1533-8
76. Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signalling. Curr Opin Immunol 1994; 6: 125-30
77. Cordle SR, Donald R, Read MA, et al. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-REL in related NF-κB proteins in human monocytic THP-1 cells. J Biol Chem 1993; 268: 11803-10
78. Savransky JE, Schaked G, Novogrodsky A, et al. Tyrphostin AG556 improves survival and reduces multi-organ failure in canine Escherichia coli peritonitis. J Clin Invest 1997; 99: 1966-73
79. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: 1097-100
80. Fisher Jr CJ, Agosti J, Opal SM, et al. Treatment of septic shock with tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697-702
81. Opal SM, Cross AS, Jhung J, et al. Potential hazards of combination immunotherapy in the treatment of experimental sepsis. J Infect Dis 1996; 173: 1415-21